Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 10:00 a.m. P.T.. This presentation will be available via webcast on the company's website under the 'Events & Presentations' section. Dynavax focuses on innovative vaccines, with two commercial products: HEPLISAV-B and CpG 1018 adjuvant, aimed at preventing hepatitis B and enhancing various vaccines, respectively.
Details
News Market Reaction – DVAX
The recorded move for DVAX in the trading session of this news was +5.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference, on Tuesday, October 18, 2022 at 10:00 a.m. P.T.
The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Contacts:
Nicole Arndt
Head of Investor Relations and Corporate Communications
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-3rd-annual-hepatitis-b-virus-virtual-conference-301649909.html
SOURCE Dynavax Technologies
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.